Introduction
Hypertension is often accompanied by type 2 diabetes mellitus. Based on insulin resistance and/or resultant hyperinsulinemia, diabetes mellitus, hypertension, lipid disorders, and atherosclerotic vascular disease are often observed in the same individuals (1) (2) (3) (4) . It takes 10 to 15 years for diabetic patients to develop nephropathy. After its development, however, hypertension is inevitable.
betes Association (ADA) (5) in January 2002, we conducted an internet survey of medical doctors in Japan to determine how the publication of the guidelines had affected their strategy for controlling BP in diabetic patients.
Methods
The internet survey was performed by CareNet ® Inc., Tokyo, which e-mailed questionnaires on May 20, 2002 to a total of 3,616 Japanese doctors in internal medicine who had been registered as having hypertensive patients. Informed consent was obtained from each doctor after a full explanation of the design, methods, and purpose of the study, and of the intended use of the collected data. By the next day, we received answers from 441 doctors who agreed to provide data (response rate: 12.2%). The study protocol was approved by the Research Review Committee of the Health Center, Keio University, Tokyo.
Questionnaires

1.
Respondents were asked to indicate the lowest BP levels at which they would start medication (threshold BP) and the highest BP levels they would try to achieve (goal BP) in hypertensive patients with diabetes mellitus. 2. The questionnaire asked which class of agent they would choose as a first-line and a second-line medication for the treatment of hypertensive patients with diabetes mellitus. 3. After answering these questions, respondents were asked whether they were aware of the 2002 ADA guidelines (5), and they were given and asked to read an outline of the ADA guidelines before proceeding. 4. Respondents were asked again to indicate the threshold BP, goal BP, and first-line and second-line agents they would use. 5. Respondents were asked if they had at least one diabetic patient who was on monotherapy with a calcium channel blocker (CCB), and if they would continue CCB monotherapy, change to an ACEI or ARB, or add an ACEI or ARB now that they had read an outline of the ADA guidelines.
Outline of 2002 ADA Guidelines
1. Taking the recent clinical mega-trials into account, the ADA guidelines (5) proposed that the BP of diabetic patients should be controlled at below 130/80 mmHg. 2. ACEIs, ARBs, β-blockers and diuretics were recommended as first-line agents. 3. In contrast, the guidelines proposed by the Guideline Subcommittee of the Japanese Society of Hypertension (JSH2000) (6) and by the Japan Diabetes Society (JDS) (9) recommended, as first-line agents, ACEIs, ARBs, long-acting dihydropyridine CCBs, and α1-blockers. 4. Although they admitted the usefulness of CCBs, they recommended avoiding CCBs as first-line agents until the results of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) are available.
Results
Regarding the age of the respondents, 31.7% were 39 years old or younger, 49.9% were 40 to 49 years old, 17.1% were 50 years old or older, and the age was unknown in 1.3%. About one half of doctors (48.3%) had already read the 2002 ADA guidelines before being given the outline.
When to Start Antihypertensive Medication and Goal BP in Patients with Diabetes Mellitus
As shown in Table 1 , the BP level at which doctors would start medication was 152/94 mmHg, and the goal was 133/83 mmHg before being given an outline of the ADA guidelines, and these values were 149/92 mmHg and 132/82 mmHg, respectively, after being given an outline of the ADA guidelines.
The goal BP was not markedly different between doctors who had read and those who had not read the ADA guidelines. The threshold BP, however, decreased more after reading the guidelines in doctors who had not previously read the ADA guidelines ( 5/ 3 mmHg) than in those who had already read ( 3/ 1 mmHg). 
Which Class of Antihypertensive Agents to Use in Patients with Diabetes Mellitus
As shown in Table 2 , before being given an outline of the ADA guidelines, the respondents most frequently selected a CCB as their first-choice agent (33.4%). However, the frequency with which CCBs were selected as a first choice was much lower in doctors who had previously read (24.8%) compared with those who had not previously read (41.2%) the ADA guidelines, and ARB use was much higher in doctors who had previously read (34.9%) compared with those who had not previously read (23.2%) the guidelines. After reading an outline of the ADA guidelines, however, 40.3% of respondents said they would select an ARB as a first-line agent, and 35.6% of respondents said they would select an ACEI. A CCB was selected as a second-line agent both by doctors who had already read and those who had not previously read ( 40%, Table 3 ) the guidelines.
CCB Monotherapy
As shown in Table 4 , 70% (n 301) of the 430 doctors had at least one patient receiving CCB monotherapy. Of these 301 doctors, 41.5% stated that they would continue CCB monotherapy, 36.6% said they would add an ACEI or ARB, and 29.7% planned to change to an ACEI or ARB after being given an outline of the ADA guidelines. There was not much difference in the intention to continue the CCB monotherapy between doctors who had already read and those who had not previously read the ADA guidelines (40.7% vs. 42.3%, Table 4 ).
Discussion
The JSH2000 guidelines (6), as well as the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI) (10) and the World Health Organization (WHO)/International Society of Hypertension (ISH) Guidelines for the Management of Hypertension (11), recommend lifestyle modification in diabetic patients with a BP of 130/85 mmHg or higher. The JSH2000 guidelines recommend starting medication when lifestyle modification for 3 to 6 months is ineffective or the patient has a BP of 140/90 mmHg or higher (6) . The ADA guidelines (5) propose that BP of diabetic patients should be controlled at below 130/80 mmHg, and a recent review from Europe (7) recommends that BP should be lower than 130-135/80 mmHg. ACEIs, ARBs, β-blockers and diuretics are recommended as first-line agents by the ADA guidelines (5), whereas the JSH2000 (6) and JDS (11) guidelines recommend ACEIs, ARBs, long-acting dihydropyridine CCBs, and α1-blockers as first-line agents.
Katayama et al. (8) reported that in April to May 1999, the actual BP at which medication was started was 172/97 mmHg, and the achieved BP was 141/81 mmHg. In the present study, the average BP level for starting medication was 152/94 mmHg, and the goal BP was 133/83 mmHg, even before doctors had been given an outline of the 2002 ADA
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ADA, American Diabetes Association; CCB, calcium channel blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor antagonist. guidelines. After doctors were given an outline of the ADA guidelines, the threshold BP decreased, especially in doctors who had not previously read the guidelines. We speculate that the tendency of Japanese doctors to choose a lower goal BP was influenced by recent evidence such as that in the Hypertension Optimal Treatment (HOT) study (12) and the ADA guidelines (5) . In Katayama's study (8) , Japanese medical doctors were using a CCB in more than 70% of their diabetic patients, whereas an ACEI was used in 45% of diabetic patients. In our study in May 2002, only 33.4% of all doctors (41.2% of doctors who had not previously read and 24.8% of those who had already read the ADA guidelines) answered that a CCB was the first-line agent in hypertensive patients with diabetes mellitus, even before being given an outline of the ADA guidelines, and 18.6% (20.9% of doctors who had not previously read and 16.3% of those who had already read the ADA guidelines) gave the same reply after reading the ADA guidelines. ACEIs and ARBs became the first-choice agents, and the frequency of monotherapy with a CCB decreased. Also, ACEI and ARB are commonly combined with CCB therapy to achieve the goal of preventing organ damage, which is considered to be the most important goal in diabetic patients. A shift of first-line agent from a CCB to an ARB was also observed in our previous study (13) . These trends favoring the use of an ACEI or ARB in diabetic patients are considered to be derived from recent evidence. In the Reduction of Endpoints in NIDDM with the A-II Antagonist Losartan (RENAAL) study (14) , an ARB, losartan, was shown to slow the progression of severe diabetic nephropathy in type-2 diabetic patients. In the Irbesartan type II Diabetic Nephropathy Trial (IDNT) (15) , the effects of an ARB, irbesartan, were superior to those of a CCB, amlodipine (15) . Furthermore, subgroup analysis in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study (16) showed that diabetic subjects receiving losartan had a significantly lower risk of cardiovascular events compared with those treated with a β-blocker, atenolol. The results from the American African Study of Kidney Disease and Hypertension (AASK) trial (17) suggested that an ACEI, ramipril, was more effective than a β-blocker, metoprolol, or a CCB, amlodipine, in slowing the reduction in glomerular filtration rate (GFR).
In the HOT study (12) , however, a CCB, felodipine, was very effective in reducing BP and cardiovascular events, especially in diabetic patients (51% risk reduction). The recently published ALLHAT data (18) suggested that a diuretic, chlorthalidone, was as effective as a CCB, amlodipine, in preventing cardiovascular events in hypertensive patients with diabetes mellitus, and even better than an ACEI, lisinopril. Preventing stroke is a very important issue in Japan, in addition to preventing ischemic heart disease, which may be why Japanese medical doctors frequently reported the choice of CCB therapy as a second-line therapy, even after reading the ADA guidelines.
A limitation of the present study is that this analysis was performed on the basis of internet research. In addition, most answers were obtained from younger medical doctors, with 81.6% being under the age of 50. Although the response rate was 12.2%, this figure was not so different from that of previous internet surveys.
In conclusion, our data suggest that the ADA guidelines had an impact on the choice of first-line agents for treatment of diabetic patients in Japan. ARBs and ACEIs may become first-line agents and CCBs second-line agents to achieve the goal BP. Further studies will be needed to investigate the effects of recent evidence, such as that of the LIFE and ALLHAT studies, on the understanding and choice of antihypertensive agents for diabetic patients by Japanese medical doctors.
